Intuitive Surgical, Inc. (ISRG)
Intuitive Surgical's Stock Jumps As Demand for Robotic Procedures Rises
Intuitive Surgical (ISRG) shares jumped Wednesday after the maker of robotic surgical devices posted much better-than-expected quarterly results and raised its guidance on increased use of its units.
Why Intuitive Surgical Is a No-Brainer for Long-Term Investors
Intuitive Surgical NASDAQ: ISRG is intuitively a good buy-and-hold stock because its industry-leading, in-demand products and services generate robust cash flow, driving consistent gains in shareholder value. The value is evident in its balance sheet and cash flow metrics, which enable it to buy back shares while investing in growth and maintaining one of the healthiest balance sheets on Wall Street.
Here's What Key Metrics Tell Us About Intuitive Surgical (ISRG) Q3 Earnings
The headline numbers for Intuitive Surgical (ISRG) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
What's Happening With ISRG Stock?
Intuitive Surgical stock (NASDAQ: ISRG) experienced an impressive 17% increase in extended trading on Tuesday, October 21, 2025, after significantly exceeding investor expectations with its Q3 results across all key metrics. The pioneer in medical robotics not only posted strong quarterly figures but also revised its full-year guidance upward, indicating ongoing momentum within the robotic surgery market.
Intuitive Surgical, Inc. (ISRG) Q3 2025 Earnings Call Transcript
Intuitive Surgical, Inc. (NASDAQ:ISRG ) Q3 2025 Earnings Call October 21, 2025 4:30 PM EDT Company Participants Dan Connally David Rosa - CEO & Director Jamie Samath - CFO, Head of Business Technology & Enterprise Technology Leader Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Travis Steed - BofA Securities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Patrick Wood - Morgan Stanley, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Adam Maeder - Piper Sandler & Co., Research Division Presentation Operator Thank you for standing by, and welcome to the Intuitive Third Quarter 2025 Earnings Release. [Operator Instructions] As a reminder, today's program is being recorded.
Intuitive Surgical beats earnings estimates on strong demand for surgical robots
Intuitive Surgical on Tuesday reported better-than-expected third-quarter profit and revenue, driven by growing demand for its surgical robots used in minimally invasive procedures.
Will Intuitive Surgical (ISRG) Beat Estimates Again in Its Next Earnings Report?
Intuitive Surgical (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Intuitive Surgical Pre-Q3 Analysis: Buy, Hold or Sell ISRG Stock Now?
Intuitive Surgical enters Q3 earnings season on strong momentum, backed by robust procedure growth and da Vinci 5 adoption. However, tariff risks and global CapEx constraints remain challenges.
Can ISRG Continue Its Strong Growth Amid Tariff & Rare Earth Woes?
ISRG's growth momentum faces pressure as tariffs and China's rare earth export curbs threaten margins and supply stability.
Why Congress Is Buying Intuitive Surgical Ahead of Earnings
Intuitive Surgical Inc. NASDAQ: ISRG is entering a potential breakout window as it heads into its next earnings report on October 21, 2025. A wave of recent developments has improved the outlook and set the stage for a possible rally leading into—or following—the announcement.
Here's Why Intuitive Surgical, Inc. (ISRG) Fell More Than Broader Market
Intuitive Surgical, Inc. (ISRG) reached $429.54 at the closing of the latest trading day, reflecting a -3.2% change compared to its last close.
ISRG Shares Rise as FDA Clears AI Integration for Ion Platform
Intuitive Surgical shares climb after FDA clears AI-driven upgrades for its Ion platform, boosting precision and efficiency in lung biopsies.
